Peer-reviewed veterinary case report
Radiation and carboplatin treatment for cat mouth cancer
By Schlueter, Andrew et al.·Published in Journal of feline medicine and surgery·2025·Washington State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of feline oral squamous cell carcinoma with accelerated radiation and carboplatin with and without follow-up toceranib phosphate.
- Species:
- cat
Plain-English summary
A group of cats with oral squamous cell carcinoma (a common mouth cancer) received accelerated radiation therapy along with a chemotherapy drug called carboplatin. Some of these cats also received a follow-up treatment with toceranib phosphate, which is thought to help fight this type of cancer. Overall, the average survival time for all cats was about 164 days, and while there was no significant difference in survival between those who received toceranib and those who did not, cats with tumors on their tongues seemed to benefit from the additional treatment, living longer without disease progression. This suggests that while toceranib may not help all cats, it could be useful for some with specific tumor locations.
People also search for: cat oral cancer treatment · feline squamous cell carcinoma radiation · toceranib phosphate for cats
Abstract
ObjectivesOral squamous cell carcinoma (SCC) is the most common oral tumor in cats but treatment options that provide long-term tumor control are limited. Radiation therapy is a reported treatment option, but local tumor control is still difficult to obtain and additional treatment options are needed. Toceranib phosphate recently emerged as having biologic activity against feline oral SCC. This study is a preliminary evaluation of radiation therapy and toceranib phosphate in cats with oral SCC.MethodsThis non-blinded, retrospective, single-institutional study included all patients between 2011 and 2023 that underwent the same treatment with accelerated radiation therapy and concurrent carboplatin as previously described, with the exception of one additional fraction of radiation. Once the early side effects abated, toceranib phosphate was offered as follow-up maintenance therapy. The median survival time (MST) and progression-free interval (PFI) were assessed for the cats that received toceranib after radiation therapy and carboplatin, and were compared with the cats that received the same radiation and carboplatin protocol within the same time period but did not receive follow-up toceranib.ResultsOverall, 47 cats met the criteria for evaluation; of them, 15 received follow-up toceranib. The MST of all cats was 164 days; there was no significant difference in MST or PFI between the cats that did and did not receive adjuvant toceranib (MST 208 days vs 162 days, respectively; = 0.35). When comparing cats with lingual tumors, the PFI was significantly longer in the cats that received toceranib than those that did not (142 days vs 104 days, respectively; = 0.045); however, there was no difference in MST (197 days vs 147 days; = 0.15).Conclusions and relevanceThis study suggests that most cats with oral SCC do not benefit from toceranib after radiation therapy. There may be clinical benefit to administering adjuvant toceranib after radiation in cats with lingual SCCs, but the mechanism remains unclear and additional studies are warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40183472/